A Swiss Team Uses Transcranial MR-Guided Focused Ultrasound to Treat Patients With Functional Brain Disorders
TIRAT CARMEL, Israel, July 14 /PRNewswire/ -- InSightec Ltd. today announced that a team at the University Children's Hospital Zurich has completed a feasibility study testing the use of non-invasive transcranial MR-guided focused ultrasound surgery (MRgFUS) for the treatment of...
Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
PLYMOUTH, Mass., July 9 /PRNewswire/ -- Harvest Technologies Corp. ( www.harvesttech.com ) announced today that the company sponsored 60-patient clinical trial conducted at Sri Ramachandra Medical Center in Chennai, India using the company's BMAC System to treat
patients with non-reconstructable...
Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
Calvert Research, LLC (a unit of Calvert Holdings, Inc.) today announced the execution of a license agreement with Tulane University granting Calvert Research (through its wholly owned subsidiary, Calvert T1, LLC) certain rights to issued patents and patent applications covering a technology plat...
Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
JERUSALEM, June 3 /PRNewswire/ -- The Gamida Cell-Teva Joint Venture
announced today that five prestigious cord blood transplantations centers in
Spain, three in Barcelona and two in Valencia, have joined the Excel study.
Participating clinical sites include, in alphabetical order:
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie,
specialised department of Pierre Fabre Laboratories, is proud to announce the
launch of a set of clinical trials following the signature of an exclusive
and worldwide licence agreement on July 10th 2008 with the University of
Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury
SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN)( http://www.BMSN.us ) and Entest BioMedical Inc., its wholly owned subsidiary, announced today they have jointly submitted a Project Summary Report to the U.S. Army Medical Research and Mater...
CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
Peptide-based vaccines could prove efficacious for both prophylactic and therapeutic treatments
VIENNA, Va., April 28 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM ) announced today that preclinical studies have demonstrated that vaccines utilizing its proprietary L.E.A.P.S....
Independent Study Corroborates Prana's Strategy to Treat Alzheimer's Disease Patients.
- Journal of Neuroscience paper describes role of Zinc in developing Alzheimer's -
MELBOURNE, Australia, April 1 /PRNewswire-FirstCall/ -- Prana Biotechnology (ASX:PBT; Nasdaq: PRAN ) today announced that an independent study conducted by researchers at the University of California, Irvine...
Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial
Central Texas man receives groundbreaking therapy days after heart attack
AUSTIN, Texas, March 31 /PRNewswire/ -- On March 30, the Heart Hospital of Austin treated the first patient in the world enrolled in a groundbreaking Phase II study designed to test the effectiveness and safety of a...
Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
Application Includes Data from a Comparative Trial in Anterior Uveitis
TAMPA, Fla., March 16 /PRNewswire/ -- Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(...
Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Therapeutic Approach Provides HIV-Resistant Immune Cells
RICHMOND, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that its collaborators at the University of Pennsylvania have opened a Phase 1 clinical trial to evaluate SB-728-T for the ...
Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
HAMBURG, Germany and STOCKHOLM, January 21 /PRNewswire/ -- Richter-Helm
BioLogics GmbH & Co. KG and Athera Biotechnologies AB have signed an
agreement for the development and manufacturing of Athera's novel product for
prevention of plaque rupture and athero-thrombosis through binding of t...
Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems
Fast form of precise radiotherapy targets tumors quickly and accurately while minimizing exposure of surrounding healthy tissue
PALO ALTO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- During his annual
physical check-up in March, David Kelver's doctor noticed he'd never had
his tonsils out,...
BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
Preservation with BioLife's Proprietary, Next Generation, Biopreservation
Media Resulted in Increased Yield and Quality of Insulin-Producing Islet Cells
BOTHELL, Wash., Oct. 24 /PRNewswire-FirstCall/ -- BioLife Solutions
Inc. (OTC Bulletin Board: BLFS), a leadi...
Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During 'Live' Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
Research Shows New Class of Stent Effective in Preventing Thrombosis, Restenosis, and Reocclusion
PARIS, Oct. 1 /PRNewswire/ -- CeloNova BioSciences, Inc., today
announced that Masahiko Ochiai MD, Associate Professor, Division of
Cardiology, Yokohama Hospital, Kanagawa, J...
Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)
Total Value of the Commitment to the CGI is an Estimated $210 Million
Crofelemer, Once Approved for Children, Could Aid in Treating Diarrhoel
Diseases That Kill An Estimated 2.5 million Children Each Year
NEW YORK, Sept. 25 /PRNewswire-USNewswire/ -- Napo Pharmaceuticals,
Inc., ("Napo") of...
Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
LOS ANGELES, California and GUANGZHOU, China, August 12
- Major Threat Treatable With StatC(TM); FDA-Approved Drugs to Begin
Testing in U.S. Animal Models
An internationally renowned avian influenza expert today hailed
"encouraging and exciting" results from exper...
Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
DALLAS, June 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.
(OTC Bulletin Board: ACCP) announced that the Company gave an oral
presentation yesterday on its monoclonal antibody product, Angiolix(R), at
the 7th International Congress on Recombinant Antibodies, held in Dublin,
Novel compound may treat acute diarrhea
In a development that may lessen the epidemic of diarrhea-related deaths among children in developing countries, scientists in the laboratory of Nobel Laureate Ferid Murad, M.D., Ph.D., at The University of Texas Health Science Center at Houston have discovered a novel compound that might lead to ...
AMITIZA(R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women
AMITIZA 8 mcg dose is the only widely available FDA-approved prescription medication for Irritable Bowel Syndrome with Constipation
BETHESDA, Md., and DEERFIELD, Ill., May 27 /PRNewswire-FirstCall/ --
Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP ) and Takeda Pharmaceuticals
Top Cancer Hospitals in Denmark and Netherlands First in Europe to Treat Patients With RapidArc(TM) Radiotherapy
New technology from Varian Medical Systems delivers faster image-guided
intensity-modulated radiotherapy (IMRT) to target tumors while sparing more healthy tissue
COPENHAGEN, Denmark and AMSTERDAM, Netherlands, May 14
/PRNewswire-FirstCall/ -- Doctors in Denmark and...
Novel Approach to Treat Alzheimer's and Other Diseases Offered by Targeting Cell Membrane RAFTS
JADO Technologies' Scientists and Collaborators Publish Study in Science
DRESDEN, Germany, April 25 /PRNewswire/ -- JADO Technologies GmbH, the
leading developer of RAFT intervention therapeutics, announced today the
publication of a paper in Science demonstrating a potential novel strategy
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Within the First Eight Months Since its Introduction in the United States, VYVANSE has Achieved Over One Million Prescriptions
In a Clinical Study With Adults, VYVANSE was Shown to Significantly Improve the Symptoms of ADHD (Inattention, Hyperactivity and Impulsivity)(1)
CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
More Than 5,000 Lung Cancer Patients Treated With CyberKnife System to Date
SUNNYVALE, Calif., March 26 /PRNewswire-FirstCall/ -- Accuray
Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery,
announced today that approximately 90 percent of CyberKnife centers
Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
RESEARCH TRIANGLE PARK, N.C., Feb. 20 /PRNewswire/ -- Addrenex
Pharmaceuticals has reached its first milestone accomplishment this year
with the filing of a new drug application (NDA) for its first drug,
CloniBID, to treat
hypertension. Upon approval from the Food and Drug
AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
WEST CHESTER, Ohio, Feb. 11 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC ), a medical device company and a leader in cardiac surgical
ablation products, today announced that the first patient was successfully
treated in AtriCure's ABLATE clinical trial. Dr. Richard Kaplon, a
Difficult to Treat Erectile Dysfunction Patients
Real Medicine Now
CHERRY HILL, N.J., Jan. 7 /PRNewswire/ -- TriMix Laboratories LLC today
announced the introduction of TriMix-gel(TM). TriMix-gel(TM) has been
suggested as an alternative for patients who fail on Viagra(R) type pills
and cannot or will not self injec...
Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
Summary: Genmab's Partner, Roche has Initiated a Phase II study of R1507 for the Treatment of Sarcoma
COPENHAGEN, Denmark, December 20 /PRNewswire-FirstCall/ -- Genmab A/S
(OMX: GEN) announced today that its partner, Roche has initiated a Phase II
clinical study of R1507 f...
BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
NOVATO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- BioMarin
Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and IGAN Biosciences announced
today that they have initiated a program to develop an IgA protease for
treating IgA nephropathy. IgA proteases have been shown to cleave IgA
complexes, the depos...
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
HORSHAM, Pa. and KENILWORTH, N.J., Nov. 6 /PRNewswire/ -- Centocor,
Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation
announced today that an estimated one million patients have now been
treated with REMICADE(R) (infliximab), the leading anti-tumor necrosis
Aida's Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
SANTA MONICA, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Aida
Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced an update
on its testing of Rh-Apo2L, the next large-scale product to be launched by
the Company into the China market. Aida previously announced that it had
Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
- Includes license of two antisense drugs in development targeting glucagon receptor and glucocorticoid receptor
- Includes research collaboration to identify antisense drugs to inhibit additional targets to treat
metabolic diseases - Conference call webcast Thursd...
FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
TITUSVILLE, N.J., Aug. 22 /PRNewswire/ -- The U.S. Food and Drug
Administration (FDA) today approved RISPERDAL(R) (risperidone) for the
treatment of schizophrenia in adolescents ages 13-17 and for the short-term
treatment of bipolar mania associated with manic or mixed episodes of
bipolar I di...
ConjuGon gets $730K to treat infections
Madison, Wis. - Injured soldiers in Iraq and Afghanistan are becoming infected with bacteria that conventional antibiotics cannot treat, but a Madison-based company is developing counter-measures.
With a $730,000 Small Business Innovation Research (SBIR) grant from the U.S. Army in hand, Co...
Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading
...urnal of Medicine claim to demonstrate that vertebroplasty, a procedure to treat
some painful spine fractures, is not effective. According to several autho...ncluded that "Percutaneous Vertebroplasty is a safe and effective method to treat
VCF. An immediate improvement in pain is expected for most patients, and di...
Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product
...tart later this year, will utilize the Company's Cartilage Repair Device, which consists of a proprietary bi-phasic, bioresorbable implant designed to treat
chondral lesions. The Company recently submitted a design dossier for CE Mark approval for its cartilage repair device; approval is expected at the en...
Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results
...ed from Brookhaven National Laboratory an exclusive worldwide license for nine patents in the United States relating to the right to use vigabatrin to treat
a wide variety of substance addictions and obsessive-compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related fo...
NeurogesX Reports Second Quarter 2009 Results
... second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat
pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the design and ti...
AOBO Announces New Product Launch
... NEW YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ --
- Jingwei Capsules treat
Allergy Symptoms -
- Complements Established Boke Nasal Spray Brand -
- Diversifies Product Offering with Capsule Formulatio...
Viral Genetics Creates Subsidiary to Develop Cancer Therapy
...als. He served as product leader for that company's lead cancer compound to treat
prostate and breast cancer.
"Metabolic disruption technology holds...Marino, California, Viral Genetics discovers and develops drug therapies to treat
infectious, autoimmune, and immunological deficiency disorders using its th...